Clinical insights for cancer outcomes in renal transplant patients

Transplantation Proceedings

Volumn 42, Issue 9 SUPPL., 2010, Pages

  Alber, J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; BOWEN DISEASE; CANCER INHIBITION; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; METASTASIS; MORTALITY; MUTAGENESIS; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; REVIEW; RISK FACTOR; SKIN CANCER; SKIN CARCINOMA; TUMOR BIOPSY; TUMOR VIRUS; WART VIRUS;

EID: 78649403415     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.006     Document Type: Article

References (33)

1. S. Hariharan, C.P. Johnson, and B.A. Bresnahan Improved graft survival after renal transplantation in the United States, 1988 to 1996 N Engl J Med 342 2000 605
2. H.U. Meier-Kriesche, J.D. Schold, and T.R. Srinivas Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era Am J Transplant 4 2004 378
3. ANZDATA: Australia and New Zealand Dialysis and Transplant Registry, 2008 http://www.anzdata.org.au/ Accessed April 30, 2010
4. B.A. Kiberd, C. Rose, and J.S. Gill Cancer mortality in kidney transplantation Am J Transplant 9 2009 1868
5. J.D. Briggs Causes of death after renal transplantation Nephol Dial Transplant 16 2001 1545
6. A. Andres Cancer incidence after immunosuppressive treatment following kidney transplantation Crit Rev Oncol Hematol 56 2005 71
7. B.L. Kasiske, J.J. Zinder, and D.T. Gilberston Cancer after kidney transplantation in the United States Am J Transplant 4 2004 905
8. A.C. Webster, J.C. Craig, and J.M. Simpson Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15 183 recipients Am J Transplant 7 2007 2140
9. A. Webster, and J. Chapman Cancer report: ANZDATA annual report 2005 ANZDATA Adelaide, Australia
10. C. Morath, M. Mueller, and H. Goldschmidt Malignancy in renal transplantation J Am Soc Nephrol 15 2004 1582
11. M.R. First, and V.R. Peddi Malignancies complicating organ transplantation Transplant Proc 30 1998 2768
12. H.M. Ramsay, A.A. Fryer, and S. Reece Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients Am J Kidney Dis 36 2000 167
13. A. Gutierrez-Dalmau, and J.M. Campistol Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review Drugs 67 2007 1167
14. G. Opelz, and B. Dohler Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 222
15. J. Dantal, M. Hourmant, and D. Cantarovich Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporine regimens Lancet 351 1998 623
16. S. Euvrard, J. Kanitakis, and A. Claudy Skin cancers after organ transplantation N Engl J Med 348 2003 1681
17. C.C. Otley, and S.L. Maragh Reduction of immunosuppression for transplant associated skin cancer: rationale and evidence of efficacy Dermatol Surg 31 2005 163
18. J.M. Campistol, J. Eris, and R. Oberbauer Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation J Am Soc Nephrol 17 2006 581
19. J.F. Buell, T.G. Gross, and E.S. Woodle Malignancy after transplantation Transplantation 80 2 Suppl 2005 S254
20. G.E. Kelly, W. Meikle, and A.G. Sheil Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation Br J Dermatol 117 1987 429
21. D.B. Yarosh, A.V. Pena, and S.L. Nay Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation J Invest Dermatol 125 2005 1020
22. P. O'Donovan, C.M. Perrett, and X. Zhang Azathioprine and UVA light generate mutagenic oxidative DNA damage Science 309 2005 1871
23. G.E. Koehl, J. Andrassy, and M. Guba Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice Transplantation 77 2004 1319
24. M. Hojo, T. Morimoto, and M. Maluccio Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530
25. M. Maluccio, V. Sharma, and M. Lagman Tacrolimus enhances transforming growth factor beta 1 expression and promotes tumor progression Transplantation 76 2003 597
26. M. Guba, P. Von Breitenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128
27. D.F. Lee, H.P. Kuo, and C.T. Chen IKKb suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway Cell 130 2007 440
28. J.M. Campistol, A. Gutierrez-Dalmau, and J.V. Torregrosa Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma Transplantation 77 2004 760
29. G. Stallone, A. Schena, and B. Infante Sirolimus for Kaposi's sarcoma in renal transplant recipients N Engl J Med 352 2005 1317
30. D. Sierka, M.S.A. Kumar, and M. Heifets Successful minimization of immunosuppression (IM) and conversion to Sirolimus (SLR) in kidney transplant recipients with post transplant lymphoproliferative disease (PTLD) and de novo nonskin malignancies (DNSM) Am J Transplant 4 suppl 8 2004 523
31. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
32. F.P. Schena, M.D. Pascoe, and J. Alberu Conversion from calcineurin inhibitors to sirolimus therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
33. Russ G, Campbell S, Walker RG, et al. Kidney transplant recipients at high risk for non-melanoma skin cancer (NMSC) may benefit from conversion to sirolimus versus continuation of calcineurin inhibitors. Presented at the American Society of Nephrology Renal Week 2009, October 27November 1, 2009